Navigation Links
Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:11/18/2013

served through 36 months in the MYDICAR high dose group are very encouraging," said Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon Corporation. "The continued clinical deterioration seen in the placebo patients receiving ongoing optimal standard therapy emphasizes the tremendous unmet medical need in people with advanced heart failure.'

In the additional two year follow up period of the CUPID 1 trial, the durability of reduced cardiovascular and terminal events previously observed in the MYDICAR high dose cohort at 12 months was maintained. The following recurrent cardiovascular and terminal events were tracked over the three years in all MYDICAR dose groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause death. The risk of pre-specified recurrent cardiovascular events through full three years of follow up was reduced by 82% in the high dose group compared to the placebo group (p=0.048, where p-value is the statistical probability of a result due to chance alone).

In addition, the survival probability over time was higher for patients in all MYDICAR dose groups compared to the placebo group, especially in the high dose group. At three years post-administration, there were 13 deaths: six in the placebo group, three in the low-dose group, three in the mid-dose group and one in the high-dose group. Finally, persistence of the vector DNA as assessed by qPCR testing was demonstrated in three high dose MYDICAR patients in whom a biopsy was feasible, but not from patients in the placebo or lower dose groups.  No safety concerns were noted during the three year follow-up period.

About the CUPID 1 Trial

Phase 2a of the CUPID 1 trial was a clinical trial using Celladon's lead product candidate MYDICAR in patients with advanced heart failure. In this 39-patient tria
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
9. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
10. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
11. Neogen Corporation Announces 2nd Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... microscopy technology that allows them to view single ... Dubbed "Complementation Activated Light Microscopy" (CALM), the new ... of magnitude finer than conventional optical microscopy, providing ... the nanometer scale. , In a paper published ... the researchers behind CALM used it to study ...
(Date:9/18/2014)... September 18, 2014 September 24 marks ... MX. ASEA is the manufacturer of the world's first ... care product, RENU28. , The Mexico City event ... Duvan Botero, and ASEA Field Leader Shawn Catmull from ... PhD in Atomic/Medical Physics from the University of Utah ...
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A ... occurring microorganisms such as bacteria, fungi, and algae ... water, methane, biomass, inorganic compounds, carbon dioxide, and ... expanding customer base and improved costs, biodegradable polymers ... economically viable alternative to conventional polymers. Primary factors ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3
... Berkeley -- Scientists who dream of shrinking computers to ... building block for both processor and memory, yet setting ... has been a challenge. , Now, University of California, ... a single atom, moving one step closer to quantum ...
... Sept. 13 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... extracellular matrix, today announced,that Jonathan Lim, MD, Halozyme,s President ... Global Life Sciences Conference to be held at,the Grand ... 2007 at 9:00,a.m. Eastern time (6:00 a.m. Pacific time). ...
... 13 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ... and commercializing proprietary product candidates principally,for use ... Malvina Laudicina has,joined Cadence,s management team as ... will lead the regulatory and quality assurance,activities ...
Cached Biology Technology:Physicists pin down spin of surface atoms 2Physicists pin down spin of surface atoms 3Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference 2Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance 2Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance 3
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... started in 2000 as an EC-FP5 four-year project, delivering ... steady progress and successful participations in several EC projects, ... Observation Network project (EU BON), to increase the ... and to extend the general dissemination of the Fauna ... has applied its novel e-Publishing tools to prepare ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Mich.---In the mating game, some female mites are mightier than ... the Russian Academy of Sciences suggests. The evidence comes, in ... In a paper published March 1 in the ... and Ekaterina Sidorchuk describe an extinct mite species in which ...
... look at possible health effects of the Gulf of Mexico,s ... begins today in towns across Louisiana, Mississippi, Alabama, and Florida. ... the largest health study of its kind ever conducted among ... comprehensive federal response to the Deepwater Horizon oil spill. The ...
... University of Maryland School of Medicine researchers have ... open doors to new, more effective treatments for excessive ... in the brain, GABA receptors and toll-like receptor 4 ... weeks in rodents that had been bred and trained ...
Cached Biology News:Mating mites trapped in amber reveal sex role reversal 2NIH launches largest oil spill health study 2University of Maryland School of Medicine study identifies genes associated with binge drinking 2University of Maryland School of Medicine study identifies genes associated with binge drinking 3University of Maryland School of Medicine study identifies genes associated with binge drinking 4
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
LabFax: Immunochemistry...
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Biology Products: